Rugby hospital charity trustee trials new radiotherapy treatment and said decision was "life-changing"

A Rugby hospital charity trustee said a new radiotherapy treatment that could help prostate cancer patients has been ‘life-changing’.

Willy Goldschmidt, president of the Friends of St Cross, was diagnosed with prostate cancer in 2017.

Following his diagnosis, he met with consultant urologist, Mr Donald MacDonald, who presented him with two curative options: surgery or radiotherapy.

Willy said being given the opportunity to receive the condensed radiotherapy schedule was ‘life-changing’.

Pictured with one of UHCW NHS Trust’s Elekta Versa HD linear accelerator systems, Research Radiographer, Vicky Sturgess and PACE-B trial participant and Research Champion, Willy Goldschmidt.placeholder image
Pictured with one of UHCW NHS Trust’s Elekta Versa HD linear accelerator systems, Research Radiographer, Vicky Sturgess and PACE-B trial participant and Research Champion, Willy Goldschmidt.

Recent evidence from an international randomised control phase III trial involving patients from University Hospitals Coventry and Warwickshire NHS Trust has shown that higher doses of targeted radiotherapy given each day over five days (called Stereotactic Body Radiotherapy – SBRT) has a high equivalent cure rate compared with the standard four-week course of radiotherapy treatment.

The PACE trials have been looking at establishing the new five-fraction SBRT treatment as the standard for localised prostate cancer.

Willy said: “During an appointment with the oncology team, which was also attended by research radiographer Vicky Sturgess, I was introduced to the SBRT trial, offering the option of a condensed radiotherapy schedule – five treatments over two weeks instead of the standard 20 over four weeks.

“The idea of a condensed radiotherapy schedule sounded appealing, with fewer hospital visits and no invasive surgery to recover from. I accepted the offer, and when I found out I had been

Pictured with one of UHCW NHS Trust’s Elekta Versa HD linear accelerator systems, which provides high-quality radiation therapy for cancer patients, are (from left to right) Mike Brown, Treatment Planning Manager; Matt Jones, Principal Clinical Scientist; Dr Andrew Chan, Consultant Clinical Oncologist, Gareth Baugh, Head of Radiotherapy Physics; Vicky Sturgess, Research Radiographer; and Stephen West, Radiotherapy Service Manager.placeholder image
Pictured with one of UHCW NHS Trust’s Elekta Versa HD linear accelerator systems, which provides high-quality radiation therapy for cancer patients, are (from left to right) Mike Brown, Treatment Planning Manager; Matt Jones, Principal Clinical Scientist; Dr Andrew Chan, Consultant Clinical Oncologist, Gareth Baugh, Head of Radiotherapy Physics; Vicky Sturgess, Research Radiographer; and Stephen West, Radiotherapy Service Manager.

randomly selected to the SBRT arm of the trial I was delighted.

“The shorter treatment schedule had minimal impact on my daily life, and I was able to carry on with my day-to-day activities as normal. I felt very well supported throughout the process

and was reassured by the clinical staff at every stage of the treatment.

“Being part of the trial means I still have follow-up checks, and my latest follow up on October 7 2025 came back with an all-clear result. I’m now eight years on from my initial diagnosis

and treatment, and it’s safe to say the treatment and follow up monitoring has been life-changing for me in that it has removed any concerns I might have had about this potentially lethal disease.

“I feel privileged to have been given the opportunity to take part in a trial that could change prostate cancer treatment for others. I now volunteer as a Research Champion for the Trust and fully advocate patients taking part in research trials.”

Prostate cancer is the number one cancer in males and every year more than 55,000 men are diagnosed with the disease in the UK.

The cancer is curable if caught early and currently most patients undergo 20 days of radiotherapy treatment - Monday to Friday, over a four-week period.

Andrew Chan, Consultant Clinical Oncologist at UHCW NHS Trust, says data from the trial, which has involved more than 870 prostate cancer patients across the world, is very encouraging.

He said: “This is a pivotal, practice-changing result because it means that for this highly prevalent cancer we are able to reduce radiotherapy treatment to only a quarter of the current standard – from 20 days to five days – with the same clinical benefits.”

Follow us
© 2026 Iconic Media Group Ltd. All rights reserved.Cookie SettingsTerms and ConditionsPrivacy notice